Longitudinal effects of dimethyl fumarate on patient-reported outcome measures in multiple sclerosis: treatment satisfaction, quality of life, depressive symptoms, sleep, and work productivity.
Abolfazli R, Sahraian MA, Shaygannejad V, Ashtari F, Shahmohammadi S, Poursadeghfard M, Baghbanian SM, Majdinasab N, Nahayati MA, Hosseini S, Azarfam JY, Navardi S, Torabi HR, Ayromlou H, Saeidi M, Talebi M, Nikseresht A, Niknam Z, Azimi A, Sedighi B, Ghiasian M, Ghalyanchi-Langroodi H, Pourakbar E, Heidari H, Kamali H, Mohammadianinejad E, Ghaffari M, Mosarrezaii A, Bayati A, Yaseri M, Shali A, Samadzadeh S.
Abolfazli R, et al.
J Clin Neurosci. 2026 Apr;146:111877. doi: 10.1016/j.jocn.2026.111877. Epub 2026 Jan 28.
J Clin Neurosci. 2026.
PMID: 41610777
Clinical Trial.
The primary endpoint, change in treatment satisfaction (TSQM-14) among previously treated patients, showed significant improvement across all domains: effectiveness (+13.01), side effects (+7.76), convenience (+35.21), and global satisfaction (+15.75) (all p < 0.001). S
…
The primary endpoint, change in treatment satisfaction (TSQM-14) among previously treated patients, showed significant improvement across al …